Literature DB >> 26732732

Examination of neurological prognostic markers in patients with respiratory syncytial virus-associated encephalopathy.

Shinichiro Morichi1, Natsumi Morishita1, Yu Ishida1, Shingo Oana1, Gaku Yamanaka1, Yasuyo Kashiwagi1, Hisashi Kawashima1.   

Abstract

No biomarker has been established as a prognostic indicator of acute encephalopathy associated with various etiological factors. In this study, we examined useful prognostic biomarkers in patients with acute encephalopathy associated with respiratory syncytial virus (RSV) infection. The subjects were 11 children with RSV-associated encephalopathy admitted to our hospital. We measured the levels of interleukin (IL)-6, brain-derived neurotrophic factor (BDNF) and nitrogen oxide (NO)x in cerebrospinal fluid collected on the day of admission. Using the pediatric cerebral performance categories (PCPC) score as a prognostic indicator, we evaluated the association between the biomarkers and neurologic prognosis. Concerning neurologic prognosis, sequelae were noted in more than 50% of the subjects. There was no association between prognosis and age/sex. Increases in the levels of all biomarkers were observed in all subjects. IL-6 and BDNF levels were correlated with PCPC score, but not with NOx. Of the biomarkers investigated, the IL-6 and BDNF levels in cerebrospinal fluid were shown to be correlated with neurologic prognosis. Because many patients with this disease had severe sequelae, assessment should be conducted by early evaluation of the biomarkers examined in this study with respect to the clinical course.

Entities:  

Keywords:  RS virus; acute encephalopathy; brain-derived neurotrophic factor (BDNF); interleukin-6; nitrogen oxide (NO); sequelae

Mesh:

Substances:

Year:  2016        PMID: 26732732     DOI: 10.3109/00207454.2016.1138951

Source DB:  PubMed          Journal:  Int J Neurosci        ISSN: 0020-7454            Impact factor:   2.292


  7 in total

Review 1.  Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection.

Authors:  Bernhard Resch
Journal:  Hum Vaccin Immunother       Date:  2017-06-12       Impact factor: 3.452

Review 2.  Neurologic Alterations Due to Respiratory Virus Infections.

Authors:  Karen Bohmwald; Nicolás M S Gálvez; Mariana Ríos; Alexis M Kalergis
Journal:  Front Cell Neurosci       Date:  2018-10-26       Impact factor: 5.505

Review 3.  Contribution of Cytokines to Tissue Damage During Human Respiratory Syncytial Virus Infection.

Authors:  Karen Bohmwald; Nicolás M S Gálvez; Gisela Canedo-Marroquín; Magdalena S Pizarro-Ortega; Catalina Andrade-Parra; Felipe Gómez-Santander; Alexis M Kalergis
Journal:  Front Immunol       Date:  2019-03-18       Impact factor: 7.561

4.  Mild encephalitis/encephalopathy with a reversible splenial lesion associated with respiratory syncytial virus infection in infants.

Authors:  Xue-Lin Li; Jinming Han; Zhong-Rui Yan; Bing-Wei Zhang; Hai-Yang Wang
Journal:  J Neurovirol       Date:  2021-07-05       Impact factor: 2.643

5.  A fatal case associated with respiratory syncytial virus infection in a young child.

Authors:  Lili Xu; Hengmiao Gao; Jiansheng Zeng; Jun Liu; Cong Lu; Xiaolei Guan; Suyun Qian; Zhengde Xie
Journal:  BMC Infect Dis       Date:  2018-05-11       Impact factor: 3.090

6.  Lung pathology due to hRSV infection impairs blood-brain barrier permeability enabling astrocyte infection and a long-lasting inflammation in the CNS.

Authors:  Karen Bohmwald; Jorge A Soto; Catalina Andrade-Parra; Ayleen Fernández-Fierro; Janyra A Espinoza; Mariana Ríos; Eliseo A Eugenin; Pablo A González; María Cecilia Opazo; Claudia A Riedel; Alexis M Kalergis
Journal:  Brain Behav Immun       Date:  2020-09-24       Impact factor: 7.217

7.  Synergism and Antagonism of Bacterial-Viral Coinfection in the Upper Respiratory Tract.

Authors:  Sam Manna; Julie McAuley; Jonathan Jacobson; Cattram D Nguyen; Md Ashik Ullah; Ismail Sebina; Victoria Williamson; E Kim Mulholland; Odilia Wijburg; Simon Phipps; Catherine Satzke
Journal:  mSphere       Date:  2022-01-19       Impact factor: 4.389

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.